Welcome to our dedicated page for ONCOLYTICS BIOTECH SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncolytics Biotech filings document a clinical-stage oncology company developing pelareorep and reporting material events through Form 8-K disclosures. Recent filings cover pelareorep study updates in metastatic colorectal cancer and squamous cell anal carcinoma, FDA-related development communications, translational data presented from GOBLET and AWARE-1, and incorporation of certain exhibits into a Form F-3 registration statement.
The company's regulatory record also documents capital-structure matters, including Nasdaq-listed ONCY common stock and an open-market sale agreement, as well as corporate-status changes tied to its completed continuance and domestication from Canadian jurisdictions to Nevada. These filings describe governance approvals, registered securities, financing arrangements, and oncology development disclosures for the issuer.
ONCOLYTICS BIOTECH INC Chief Financial Officer Kirk Look received a grant of stock options covering 260,000 common shares as compensation. The options have an exercise price of $1.06 per share, equal to the closing price on June 1, 2026, and expire on June 1, 2036.
The award vests in three equal annual installments, with the first tranche vesting on June 1, 2027, contingent on his continued service or employment on each vesting date. This filing reflects a routine equity incentive grant, with no open-market share purchases or sales reported.
ONCOLYTICS BIOTECH INC Chief Business Officer Andrew Aromando received a grant of 260,000 stock options. These options have an exercise price of $1.06 per share, equal to the closing price of the company’s common stock on the Nasdaq Capital Market on June 1, 2026.
The options cover 260,000 underlying common shares and expire on June 1, 2036. They vest in three equal annual installments, with the first tranche vesting on June 1, 2027, subject to his continued service or employment on each vesting date.
ONCOLYTICS BIOTECH INC director Stephen C. Glover has filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The filing lists his role as a director and shows no reported transactions or current derivative positions.
ONCOLYTICS BIOTECH INC reported a Form 4 for Chief Executive Officer Jared Kelly showing a compensation-related grant of stock options. He received options for 755,000 common shares at an exercise price of $1.06 per share, equal to the Nasdaq closing price on June 1, 2026.
The options expire on June 1, 2036 and vest in three equal annual installments starting on June 1, 2027, contingent on continued service. Following this award, his reported stock option holdings from this grant total 755,000 options.
ONCOLYTICS BIOTECH INC director Patricia S. Andrews received a grant of stock options covering 30,000 common shares. The options have an exercise price of $1.06 per share, equal to the closing price on the Nasdaq Capital Market on June 1, 2026, and expire on June 1, 2036.
The award vests in three equal annual installments, with the first tranche vesting on June 1, 2027, as long as she continues in service or employment on each vesting date. Following this grant, she holds 30,000 stock options directly.
ONCOLYTICS BIOTECH INC director Bernd R. Seizinger received a grant of stock options covering 30,000 common shares. The options have an exercise price of $1.06 per share, matching the closing price on the Nasdaq Capital Market on June 1, 2026, and expire on June 1, 2036.
The award vests in three equal annual installments starting on June 1, 2027, contingent on his continued service or employment on each vesting date. Following this grant, he holds stock options on 30,000 shares directly.
ONCOLYTICS BIOTECH INC reported that Chief Technology Officer Allison Hagerman received a grant of stock options covering 260,000 Common Shares. The options have an exercise price of $1.06 per share, matching the Nasdaq Capital Market closing price on June 1, 2026, and expire on June 1, 2036.
The award vests in three equal annual installments, with the first tranche vesting on June 1, 2027, conditioned on continued service or employment. Following this grant, Hagerman holds 260,000 stock options directly, and the filing does not show any share purchases or sales.
ONCOLYTICS BIOTECH INC director Deborah Margaret Brown received a stock option grant for 30,000 common shares. The option has an exercise price of $1.06 per share, matching the Nasdaq Capital Market closing price on June 1, 2026, and expires on June 1, 2036.
The award vests in three equal annual installments starting on June 1, 2027, conditioned on her continued service or employment on each vesting date. Following this grant, she holds options for 30,000 underlying common shares as reported in this filing.
ONCOLYTICS BIOTECH INC reported that Chief Medical Officer Thomas Charles Heineman received a grant of stock options as part of his compensation. The award covers 260,000 stock options for common shares at an exercise price of $1.06 per share, matching the closing price on June 1, 2026. These options expire on June 1, 2036 and vest in three equal annual installments starting on June 1, 2027, conditional on his continued service or employment on each vesting date. After this grant, he holds 260,000 stock options directly.
Oncolytics Biotech Inc. reported that Chief Operating Officer John Bearden McAdory received a grant of stock options as part of his compensation. He was awarded options covering 145,000 common shares at an exercise price of $1.06 per share, equal to the Nasdaq Capital Market closing price on June 1, 2026.
The options vest in three equal annual installments, with the first tranche vesting on June 1, 2027, as long as he continues in service or employment on each vesting date. The options expire on June 1, 2036. This is a derivative award, not an open-market stock purchase or sale.